DRG Market Assessment reports

Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of eosinophilic esophagitis (EoE) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States…

Primary membranous nephropathy (pMN), the most common type of MN, is a rare autoantibody-mediated autoimmune kidney disease. Despite being one of the leading causes of nephrotic syndrome in…

Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key idiopathic pulmonary fibrosis (IPF) patient populations, covering…

Muscular dystrophy (MD) is a spectrum of genetic disorders characterized by muscle weakness that, in severe forms, can lead to loss of ambulation and early mortality. The standard treatment for MD…

The PsA therapy market is undergoing significant transformation with the emergence of new treatment options, intensifying competition for favorable payer coverage. TNF-α inhibitors, such as AbbVie…

Acute myeloid leukemia (AML) is associated with poor outcomes and low five-year overall survival rates. Although chemotherapy has long been the mainstay of AML treatment, the recent approval of new…

Biosimilar regulations and guidance have been defined, at least in draft form, in most the world’s leading pharmaceutical markets. In many cases, biosimilar guidance is based on that of the EMA,…

Clarivate Epidemiology’s coverage of glioma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and diagnosed…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key glioma patient populations, covering 171 countries and more than 99…